Regulus Therapeutics Inc., a biopharmaceutical company, focuses on
the discovery and development of drugs that target microRNAs for the
treatment of various diseases in the United States. The company uses its
microRNA product platform to develop anti-miRs, which is chemically
modified and single-stranded oligonucleotide. The company has strategic
collaboration with Biogen Idec MA Inc. for the evaluation of the use of
microRNA signatures as a biomarker for human patients with multiple
sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics
for cardiovascular diseases, metabolic diseases, and oncology; and
GlaxoSmithKline plc to discover and develop microRNA therapeutics for
immuno-inflammatory diseases. It also has strategic collaboration with
Sanofi for the discovery and development of microRNA therapeutics
comprising miR-21 pre-clinical fibrosis program for the treatment of
alport syndrome and preclinical program for oncology indications.
Take a look at the 1-year chart of Regulus (Nasdaq: RGLS) below with my added notations:
RGLS had steadily went nowhere from April until mid-October. Then,
the stock jumped massively on route to hitting a new high just above
$25. Since that time, the stock has created an obvious resistance at $20
(green). A break above that $20 level should mean higher prices for the
stock.
The Tale of the Tape: RGLS has a key level of
resistance at $20. A long trade could be entered on a break through that
level. However, if you are bearish on the stock, a short trade could be
made on any rallies up to $20.
Please share this article
No comments:
Post a Comment